Skip to main content

Table 3 Neutralising antibody immune responses to homologous and heterologous H5N1 influenza strains following one or two doses of the AS03A-adjuvanted A/Indonesia/5/2005 (H5N1) influenza vaccine in terms of seropositivity rates and seroconversion rates.

From: A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

Antibody Time point N Seropositivity % (95% CI) N Seroconversion % (95% CI)
A/Indonesia PRE 99 11.1 (5.7-19.0) -- --
  Day 42 100 100 (96.4-100) 99 97.0 (91.4-99.4)
  Day 182 99 100 (96.3-100) 98 93.9 (87.1-97.7)
A/Vietnam PRE 100 50.0 (39.8-60.2) -- --
  Day 42 100 95.0 (88.7-98.4) 100 47.0 (36.9-57.2)
  Day 182 99 92.9 (86.0-97.1) 99 58.6 (48.2-68.4)
  1. Subjects received one dose of vaccine on Day 0 and one dose on Day 21 (ATP cohort for immunogenicity and persistence).
  2. Seroconversion rate for MN antibodies: Percentage of subjects with at least four-fold increase post-vaccination neutralising antibody titres.